NCT07128576View on ClinicalTrials.gov

Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

August 15, 2027

Study Completion Date

December 31, 2028

Conditions
Solid Tumors
Interventions
DRUG

Romiplostim N01

Romiplostim N01: 3-10 μg/kg(Initial dose 3 μ g/kg), qw, H.

All Listed Sponsors
lead

Zhujiang Hospital

OTHER

NCT07128576 - Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter